Isolation and characterisation of a human anti-idiotypic scFv used as a surrogate tumour antigen to elicit an anti-HER-2/neu humoral response in mice

British Journal of Cancer

Volumn 90, Issue 10, 2004, Pages 2032-2041

  Coelho, M ^a   Gauthier, P ^a   Pugniere M ^b   Roquet, F ^b   Pelegrin A ^a   Navarro Teulon, I ^a,c  

^a INSERM   (France)

^b CNRS   (France)

^c INSTITUT DE RECHERCHE EN CANCÉROLOGIE DE MONTPELLIER   (France)

Author keywords

Active immunotherapy; Anti idiotypic antibody; HER 2 neu; Vaccine

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; IDIOTYPIC ANTIBODY; MONOCLONAL ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TRASTUZUMAB F FRAGMENT; TUMOR ANTIGEN; UNCLASSIFIED DRUG; ANTIIDIOTYPIC ANTIBODY; CANCER VACCINE; IMMUNOGLOBULIN FRAGMENT;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PURIFICATION; ARTICLE; BIOSENSOR; CANCER; CANCER IMMUNIZATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; ANTIBODY PRODUCTION; CELL CULTURE; CHO CELL; CRICETULUS; HAMSTER; IMMUNOLOGY; IMMUNOTHERAPY; OVARY TUMOR; PATHOLOGY;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODY FORMATION; ANTIGENS, NEOPLASM; CANCER VACCINES; CHO CELLS; CRICETINAE; CRICETULUS; FEMALE; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOTHERAPY; MICE; OVARIAN NEOPLASMS; RECEPTOR, ERBB-2; TUMOR CELLS, CULTURED;

EID: 2942544476     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601825     Document Type: Article

References (43)

1. Baral R, Sherrat A, Das R, Foon KA, Bhattacharya-Chatterjee M (2001) Murine monoclonal anti-idiotypic antibody as a surrogate antigen for human Her-2/neu. Int J Cancer 92: 88-95
2. Bargmann CI, Hung MC, Weinberg RA (1986) The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 319: 226-230
3. Baselga J, Albanell J (2001) Mechanism of action of anti-HER2 monoclonal antibodies. Ann Oncol 12: S35-S41
4. Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R, Soper JT, Dodge R, Clarke-Pearson DL, Marks P (1990) Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 50: 4087-4091
5. Bhattacharya-Chatterjee M, Chatterjee SK, Vasile S, Seon BK, Kohler H (1988) Idiotype vaccines against human T cell leukemia. II. Generation and characterization of a monoclonal idiotype cascade (Ab1, Ab2, and Ab3). J Immunol 141: 1398-1403
6. Bhattacharya-Chatterjee M, Foon KA, Kohler H (1991) Anti-idiotype monoclonal antibodies as vaccines for human cancer. Review]. Int Rev Immunol 7: 289-302
7. Casey JL, Keep PA, Chester KA, Robson L, Hawkins RE, Begent RH (1995) Purification of bacterially expressed single chain Fv antibodies for clinical applications using metal chelate chromatography. J Immunol Methods 179: 105-116
8. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Woher JM, Paton V, Shak S, Lieberman G, Slamon DJ (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639-2648
9. Concetti A, Amici A, Petrelli C, Tibaldi A, Provinciali M, Venanzi FM (1996) Autoantibody to p 185erbB2/neu oncoprotein by vaccination with xenogenic DNA. Cancer Immunol Immunother 43: 307-315
10. Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, Seeburg PH, Libermann TA, Schlessinger J, Francke U, Levinson A, Ullrich A (1985) Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230: 1132-1139
11. Dakappagari NK, Douglas DB, Triozzi PL, Stevens VC, Kaumaya PT (2000) Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine. Cancer Res 60: 3782-3789
12. Di Carlo E, Rovero S, Boggio K, Quaglino E, Amici A, Smorlesi A, Forni G, Musiani P (2001) Inhibition of mammary carcinogenesis by systemic interleukin 12 or p 185neu DNA vaccination in Her-2/neu transgenic BALB/c mice. Clin Cancer Res 7: 830s-837s
13. Disis ML, Calenoff E, McLaughlin G, Murphy AE, Chen W, Groner B, Jeschke M, Lydon N, McGlynn E, Livingston RB, Moe R, Cheever MA (1994) Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 54: 16-20
14. Disis ML, Gooley TA, Rinn K, Davis D, Piepkorn M, Cheever MA, Knutson KL, Schiffman K (2002) Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 20: 2624-2632
15. Disis ML, Gralow JR, Bernhard H, Hand SL, Rubin WD, Cheever MA (1996) Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein. J Immunol 156: 3151-3158
16. Disis ML, Shiota FM, Cheever MA (1998) Human HER-2/neu protein immunization circumvents tolerance to rat neu: a vaccine strategy for 'self' tumour antigens. Immunology 93: 192-199
17. Dunn PL, Johnson CA, Styles JM, Pease SS, Dean CJ (1987) Vaccination with syngeneic monoclonal anti-idiotype protects against a tumour challenge. Immunology 60: 181-186
18. Fisk B, Blevins TL, Wharton JT, Ioannides CG (1995) Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 181: 2109-2117
19. Foon KA, John WJ, Chakraborty M, Das R, Teitelbaum A, Garrison J, Kashala O, Chatterjee SK, Bhattacharya-Chatterjee M (1999) Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. J Clin Oncol 17: 2889-2895
20. Foon KA, Lutzky J, Baral RN, Yannelli JR, Hutchins L, Teitelbaum A, Kashala OL, Das R, Garrison J, Reisfeld RA, Bhattacharya-Chatterjee M (2000) Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. J Clin Oncol 18: 376-384
21. Francisco JA, Gilliland LK, Stebbins MR, Norris NA, Ledbetter JA, Siegall CB (1995) Activity of a single-chain immunotoxin that selectively kills lymphoma and other B-lineage cells expressing the CD40 antigen. Cancer Res 55: 3099-3104
22. Galfre G, Monaci P, Nicosia A, Luzzago A, Felici F, Cortese R (1996) Immunization with phage-displayed mimotopes. Methods Enzymol 267: 109-115
23. Goletz S, Christensen PA, Kristensen P, Blohm D, Tomlinson I, Winter G, Rarsten U (2002) Selection of large diversities of antiidiotypic antibody fragments by phage display. J Mol Biol 315: 1087-1097
24. Jerne NK (1974) Towards a network theory of the immune system. Ann Immunol (Paris) 125C: 373-389
25. Kennedy RC, Dreesman GR, Butel JS, Lanford RE (1985) Suppression of in vivo tumor formation induced by simian virus 40-transformed cells in mice receiving antiidiotypic antibodies. J Exp Med 161: 1432-1449
26. Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R (1992) Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 327: 1209-1215
27. Leitzel K, Teramoto Y, Sampson E, Mauceri J, Langton BC, Demers L, Podczaski E, Harvey H, Shambaugh S, Volas G, Weaver S, Lipton A (1992) Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients. J Clin Oncol 10: 1436-1443
28. Magliani W, Polonelli L, Conti S, Salati A, Rocca PF, Cusumano V, Mancuso G, Teti G (1998) Neonatal mouse immunity against group B streptococcal infection by maternal vaccination with recombinant anti-ssidiotypes [see comments]. Nat Med 4: 705-709
29. Mittelman A, Chen ZJ, Kageshita T, Yang H, Yamada M, Baskind P, Goldberg N, Puccio C, Ahmed T, Arlin Z, Ferrone S (1990) Active specific immunotherapy in patients with melanoma A clinical trial with mouse antiidiotypic monoclonal antibodies elicited with syngeneic anti-high-molecular-weight-melanoma- associated antigen monoclonal antibodies [published erratum appears in J Clin Invest 1991; 87(2): 757]. J Clin Invest 86: 2136-2144
30. Nanda NK, Sercarz EE (1995) Induction of anti-self-immunity to cure cancer. Cell 82: 13-17
31. Nelson KA, George E, Swenson C, Forstrom JW, Hellstrom KE (1987) Immunotherapy of murine sarcomas with auto-anti-idiotypic monoclonal antibodies which bind to tumor-specific T cells. J Immunol 139: 2110-2117
32. Nilsson F, Tarli L, Viti F, Neri D (2000) The use of phage display for the development of tumour targeting agents. Adv Drug Deliv Rev 43: 165-196
33. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA, Slamon DJ (1998) Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16: 2659-2671
34. Peoples GE, Goedegebuure PS, Smith R, Linehan DC, Yoshino I, Eberlein TJ (1995) Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci USA 92: 432-436
35. Pilon SA, Piechocki MP, Wei WZ (2001) Vaccination with cytoplasmic ErbB-2 DNA protects mice from mammary tumor growth without anti-ErbB-2 antibody. J Immunol 167: 3201-3206
36. Pini A, Viti F, Santucci A, Carnemolla B, Zardi L, Neri P, Neri D (1998) Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J Biol Chem 273: 21769-21776
37. Rilke F, Colnaghi MI, Cascinelli N, Andreola S, Baldini MT, Bufalino R, Delia Porta G, Menard S, Pierotti MA, Testori A (1991) Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer 49: 44-49
38. Saha A, Chatterjee SK, Foon KA, Primus FJ, Bhattacharya-Chatterjee M (2003) Murine dendritic cells pulsed with an anti-idiotype antibody induce antigen-specific protective antitumor immunity. Cancer Res 63: 2844-2854
39. Shepard HM, Lewis GD, Sarup JC, Fendly BM, Maneval D, Mordenti J, Figari I, Kotts CE, Palladino Jr MA, Ullrich A (1991) Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic. J Clin Immunol 11: 117-127
40. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182
41. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792
42. Tripathi PK, Qin H, Deng S, Xu C, Bhattacharya-Chatterjee M, Foon KA, Chatterjee SK (1998) Antigen mimicry by an anti-idiotypic antibody single chain variable fragment. Mol Immunol 35: 853-863
43. Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR (1994) Making antibodies by phage display technology. Anna Rev Immunol 12: 433-455